Precision Cardiology: Phenotype-targeted Therapies for HFmrEF and HFpEF.
Giuseppe M C RosanoCristiana VitaleIlaria SpoletiniPublished in: International journal of heart failure (2024)
Heart failure with mid-range ejection fraction (HFmrEF) and preserved ejection fraction (HFpEF) represent over half of heart failure cases but lack proven effective therapies beyond sodium-glucose cotransporter 2 inhibitor and diuretics. HFmrEF and HFpEF are heterogeneous conditions requiring precision phenotyping to enable tailored therapies. This review covers concepts on precision medicine approaches for HFmrEF and HFpEF. Areas discussed include HFmrEF mechanisms, anti-inflammatory and antifibrotic treatments for obesity-related HFpEF, If inhibition for HFpEF with atrial fibrillation, and mineralocorticoid receptor antagonism for chronic kidney disease-HFpEF. Incorporating precision phenotyping and matched interventions in HFmrEF and HFpEF trials will further advance therapy compared to blanket approaches.
Keyphrases
- ejection fraction
- heart failure
- atrial fibrillation
- aortic stenosis
- chronic kidney disease
- high throughput
- anti inflammatory
- metabolic syndrome
- left ventricular
- weight loss
- cardiac resynchronization therapy
- left atrial
- skeletal muscle
- cardiac surgery
- bone marrow
- left atrial appendage
- acute kidney injury
- catheter ablation